Vernalis
Biotechnology Research • 
Cambridge, England, United Kingdom • 201-500 Employees
Company overview
| Headquarters | Granta Park, Great Abington, Cambridge, Cambs CB21 6GB, GB |
| Phone number | +441189773133 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Oncology, Drug Discovery, Drug Development, ITC, Cheminformatics, Dmpk, NMR, CNS, Cell Biology, Biophysics, Medicinal Chemistry, SPR, Structural Biology, Protein Engineering, Synthetic Organic Chemistry, Molecular Modelling, Structure-Based, Fbld, X-Ray Crystallography, Assay Technology |
| Founded | 1997 |
| Employees | 201-500 |
| Socials |
Key Contacts at Vernalis
Ben Davis
Director Of Business Development
Mark Andersen
Director Marketing
Kerry Waters
Commercial Director
James Davidson
Director Of Chemistry
Clare Searle
Joint Site Lead & Finance Director
Mike Wood
Research Director
Brian Tighe
Regional Sales Director
Terry Hart
Director Of Chemistry
James Murray
Research Director
Kipping Armin
Ceo
Vernalis Email Formats
Vernalis uses 3 email formats. The most common is {first initial}.{last name} (e.g., j.doe@vernalis.com), used 83.6% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@vernalis.com | 83.6% |
{first name}.{last name} | john.doe@vernalis.com | 13.1% |
{last name}.{last name} | doe.doe@vernalis.com | 3.3% |
About Vernalis
We develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation. Our established group of experienced scientists is based at our fully-equipped research laboratories on Granta Park, Cambridge UK. We integrate fragment-based approaches, structural biology, biophysics, assay technology and molecular modelling with extensive medicinal chemistry expertise to enable drug discovery on both established and novel targets. We have the experience and capabilities for progressing projects from target identification through to clinical candidate. We have generated lead compounds on kinases, ATPases, protein-protein interactions and GPCRs, leading to clinical candidates for Chk1, Hsp90, Bcl-2, Mcl-1, FAAH and A2A. We balance an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Our shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and we seek additional partnerships.
Vernalis revenue & valuation
| Annual revenue | $11,500,000 |
| Revenue per employee | $48,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $36,600,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Vernalis has 112 employees across 14 departments.
Departments
Number of employees
Vernalis Tech Stack
Discover the technologies and tools that power Vernalis's digital infrastructure, from frameworks to analytics platforms.
Security
JavaScript libraries
Maps
JavaScript libraries
Font scripts
JavaScript libraries
Webmail
Programming languages
Blogs
Analytics
UI frameworks
Italy
Canada
Spain
Frequently asked questions
4.8
40,000 users
